ULC0085T_S41
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ALLOGRAFT_REJECTION+0.480
- ANGIOGENESIS+0.410
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.390
- IL6_JAK_STAT3_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.320
- INTERFERON_GAMMA_RESPONSE+0.290
- SPERMATOGENESIS+0.240
- KRAS_SIGNALING_DN+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.540
- CHOLESTEROL_HOMEOSTASIS-0.480
- ADIPOGENESIS-0.450
- OXIDATIVE_PHOSPHORYLATION-0.450
- FATTY_ACID_METABOLISM-0.420
- PEROXISOME-0.420
- ANDROGEN_RESPONSE-0.390
- HEME_METABOLISM-0.350
- MTORC1_SIGNALING-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168603 | — | — | 0.847 |
| 2 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.828 |
| 3 | MDT-AP-0374 | Med | Medulloblastoma | 0.826 |
| 4 | SRR23303766 | — | — | 0.818 |
| 5 | GSM5359446 | — | — | 0.818 |
| 6 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.814 |
| 7 | BS_PGHK1JRW | ATRT | — | 0.806 |
| 8 | MNG1096 | — | — | 0.789 |
| 9 | MNG1010 | — | — | 0.784 |
| 10 | MBCProject_0582_T1_RNA | — | D | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |